Author: healthadmin

Physicians’ use of artificial intelligence has more than doubled since 2023, with an American Medical Association survey reporting that 81% currently use the technology in professional settings. Additionally, approximately 1,700 physician respondents surveyed in January and February reported an average of 2.3 use cases. This is also up from an average of 1.1 use cases in 2023, when organizations first began their near-annual poll on the topic. Most common among physician users were applications focused on documenting clinical care and summarizing medical research. The AMA noted that the percentage of physicians using AI in research summaries and standard of care…

Scientists from the University of Almería and the University of Granada, in collaboration with researchers from the Leiden University Medical Center (LUMC, the Netherlands), have identified gut bacteria of the genus Roseburia that are associated with stronger muscles and improved physical condition. This result supports the concept of a gut-muscle axis. “Taken together, our findings provide solid evidence supporting the existence of a gut-muscle axis in which this identified bacterium actively regulates muscle metabolism and muscle strength,” says Jonathan Lewis, professor in the UGR Faculty of Physical Education and Sport and researcher at the Interuniversity Research Institute for Sport and…

New research in the March 2026 issue JNCCN – National Comprehensive Cancer Network Journal It has been suggested that exercise, through chemotherapy given in fortnightly cycles, may help cancer patients become mentally sharp and better able to cope with daily life, work and social activities. In this first-of-its-kind, national, multicenter, Phase III trial, patients were randomly assigned to receive an exercise prescription, Exercise for Patients with Cancer (EXCAP©®). In addition to regular chemotherapy, this regimen includes personalized walking and simple resistance band exercises. By the end of the study, patients who underwent two-week chemotherapy cycles and followed the EXCAP exercise…

During their quarterly conference call, Legend Biotech executives expressed little concern about new threats to the company’s only commercial product, the multiple myeloma CAR-T Carvykti. Oddly enough, this competition is being conducted through Karvicti’s commercial partner, Johnson & Johnson. Over the past three months, the pharmaceutical giant has announced data from two successful trials of its multiple myeloma bispecific Tecvayli. One in combination with J&J’s Darzalex and the other with BCMAxCD3 T-cell engager as a single agent. The results of the study show a competitive profile compared to Carvykti, and the combo quickly won FDA approval last week. During Tuesday’s…

Young people with depression exhibit abnormal cellular energy patterns in both the brain and blood, characterized by overactive cells at rest, but unable to respond appropriately to physical stress. This biological manifestation of fatigue suggests that early medical intervention may help restore cellular balance before long-term physical damage occurs. The study was published in the journal translational psychiatry. Fatigue is a common and disabling symptom of major depressive disorder. Despite the prevalence of this severe fatigue, its biological origins remain largely a mystery. Medical professionals need a clearer picture of how depression changes the body at a microscopic level to…

Researchers have developed a capsule-based method that allows them to analyze the same cells through multiple experimental steps. This technology could overcome long-standing limitations in cell research and open new ways to study disease mechanisms at the single-cell level. In a study published in a scientific journal scienceVisiting Professor Linas Mazutis and his research team at Umeå University have presented a new technique for analyzing individual cells. This method addresses long-standing technical challenges in cell research. Until now, scientists have typically been able to analyze each cell only once, making it difficult to study how individual cells change or respond…

The Trump administration’s campaign to make America’s soil healthy again has a dirty side. At times, the plan sounds like it was written by Democrats. Groups that cheered the Biden administration’s climate-smart agriculture efforts are hearing familiar echoes in the USDA’s new regenerative agriculture pilot program that pays farmers to choose from a list of Washington-approved conservation practices. Just a few years ago, Republicans might have balked at the concept and resisted teaching farmers how to farm. It’s now a pillar of the Republican administration’s “Make America Healthy Again” policy, which argues that healthier soils and less pesticide use will…

Recent research published in journals addictive behavior Evidence shows that almost one in five people who seek help for a gambling problem experience suicidal thoughts. This study suggests that factors such as overwhelming debt and lack of social support increase this risk for both men and women. These findings highlight the serious mental health consequences of gambling addiction and point to the need for stronger prevention and support systems. The researchers wanted to identify specific mechanisms that contribute to gambling-related suicides in both genders. Past evidence suggests that the relationship between gambling and suicidal ideation is highly complex. It is…

While much of the company’s recent focus remains on strengthening U.S. infrastructure, Eli Lilly has moved for the second time this week to increase drug manufacturing capacity overseas, and again in Asia. The company announced Thursday a 20 billion yen (approximately $126 million) expansion of its Seishin factory in Kobe. Lilly’s local unit plans to install a new production line there and add a new warehouse by 2028, according to a Japanese press release (PDF). Lilly did not say which medicines the expansion would support, but Nikkei Asia reported on March 12 that the project would boost manufacturing of drugs…

The FDA is retiring the old and introducing a new one, announcing a new adverse event surveillance system that combines multiple reporting systems into one integrated platform. The initiative is expected to save approximately $120 million over the next five years. The program, called the FDA Adverse Event Monitoring System (AEMS), is consistent with FDA’s mission to “modernize the safety of regulated products and provide radical transparency,” the agency said in a March 11 press release. FDA Commissioner Marty McCurry, M.D., said the current adverse event reporting system is “outdated and fragmented,” wasting “millions of taxpayer dollars” and creating blind…